Spike Protein News and Research

RSS

Host and in vitro genomic variability of SARS-CoV-2 and its variants

Researchers from the University of Sydney investigate the genomic variability of SARS-CoV-2 within the host and in vitro.

30 Nov 2021

Structure-guided virtual screening identifies novel SARS-CoV-2 Mpro inhibitors

A new paper deals with the identification of an antiviral compound that could help in developing additional drugs to help fight COVID-19.

30 Nov 2021

Anti-SARS-CoV-2 antibodies suggested to be safe to use in pregnancy

Pregnant patients with mild to moderate COVID-19 were treated with MAb and reported no adverse effects.

30 Nov 2021

Human LRRC15 protein is an inhibitory receptor for SARS-CoV-2 spike-mediated entry

In a recent study, published on the bioRxiv* preprint server, researchers identified human LRRC15 as an inhibitory receptor for SARS-CoV-2 entry, which directly binds to the receptor-binding domain (RBD) of the spike protein with a moderate affinity and inhibits spike-mediated entry.

29 Nov 2021

SARS-CoV-2 Delta spike increases viral virulence and inflammatory cytokine production

In a new study published on the bioRxiv* preprint server, scientists investigated several virological features of the Delta spike protein.

29 Nov 2021

Targeted measures to prevent the spread of Omicron variant take effect from 30 November 2021

Targeted measures to prevent the spread of the new COVID-19 Omicron variant take effect from 4am today [Tuesday 30 November].

29 Nov 2021

Extended host range for SARS-CoV-2 variants of concern

Researchers used viral pseudotyping to examine whether variants of concern had different host ACE2 receptor usage patterns.

29 Nov 2021

Immunity found 6 months after SARS-CoV-2 infection in children

A new study suggests that infection-induced antibodies persist, providing protection for at least six months.

29 Nov 2021

Do we need COVID-19 vaccine boosters?

An article published recently in the Journal of Virology explored the science behind COVID-19 vaccine boosters.

29 Nov 2021

Study suggests making COVID vaccines based on Mu variant

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Mu variant (B.1.621, B.1.621.1) has been tagged as a Variant Being Monitored (VBM), and as of August 30, 2021, it had been detected in 39 countries.

28 Nov 2021

Identifying the spread of novel B.1.1.523 SARS-CoV-2

In their recent study, researchers from Lithuania have reported the emergence of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant lineage B.1.1.523 containing a set of mutations associated with immune escape, including deletion 156_158del, substitution E484K and S494P in Spike (S) protein.

28 Nov 2021

An analysis of SARS-CoV-2 breakthrough infections by variant and vaccine

Researchers compared the distribution of SARS-CoV-2 genotypes to the prevalence of SARS-CoV-2 variants.

28 Nov 2021

The introduction and rapid spread of SARS-CoV-2 Gamma in Venezuela

Researchers from the Instituto Venezolano de Investigaciones Científica investigate the introduction of one of the VOCs into Venezuela.

28 Nov 2021

SARS-CoV-2 Omicron variant: What we know so far

On November 24, 2021, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant was first reported to the World Health Organization (WHO) from South Africa.

28 Nov 2021

Government introduces precautionary travel restrictions on arrivals from South Africa

The government is taking decisive precautionary action against a new COVID-19 variant by introducing travel restrictions on arrivals from South Africa, Botswana, Lesotho, Eswatini, Zimbabwe and Namibia from midday tomorrow (Friday 26 November).

25 Nov 2021

A review of natural immunity, vaccines, and variants in SARS-CoV-2 reinfection

In a literature review article published in the Journal of Community Hospital Internal Medicine Perspectives, authors from the US performed a thorough investigation of previous studies and case reports of SARS-CoV-2 reinfection. This review discusses the role of natural immunity, vaccines, and SARS-CoV-2 variants in reinfection.

25 Nov 2021